Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.59 |
| ▸ | RCE1 | Q9Y256 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28405143 | 0.90 | RCE1 (0.61) | KMT2ARCE1MEN1SMN1; SMN2MAPT | |
| SCHEMBL28359204 | 0.85 | KMT2A (0.77) | KMT2ARCE1MEN1CNR1S1PR3 | |
| SCHEMBL13580881 | 0.79 | NR1H4 (0.42) | KMT2AMEN1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL2644697 | 0.77 | RCE1 (0.38) | KMT2ARCE1MEN1LMNANR1H4 | |
| Bromobenzene SCHEMBL9230161 | 0.75 | ALDH1A1 (0.55) | KMT2AMEN1SMN1; SMN2MAPTMAPK1 | |
| SCHEMBL12974482 | 0.75 | ALDH1A1 (0.59) | RCE1MAPK1LMNAALDH1A1NR1H4 | |
| SCHEMBL240963 | 0.74 | ALDH1A1 (0.53) | KMT2ARCE1MEN1SMN1; SMN2MAPT | |
| SCHEMBL15457872 | 0.74 | NR1H4 (0.34) | KMT2ARCE1MEN1SMN1; SMN2MAPT | |
| SCHEMBL13580884 | 0.74 | ALDH1A1 (0.37) | KMT2ARCE1ALDH1A1HDAC1 | |
| SCHEMBL28407865 | 0.73 | KMT2A (0.51) | KMT2ARCE1MEN1S1PR3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8633245-B2 | PAI-1 inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2014-01-21 | — | — | US | disclosed |
| US-20090312315-A1 | PAI-1 INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312315-A1 | PAI-1 INHIBITOR | SERPINC1, SERPINE1, SERPINH1 | KMT2A 2586/4885RCE1 378/4885MEN1 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.